ADVERTISEMENT
ADVERTISEMENT
site_logo
  • Campus
  • Happening
  • Opinion
  • People
  • News
  • #BeInspired
  • Careers
  • 40 under 40
  • Exams
  • What The FAQ
  • Videos
    • Straight Up
    • Odisha Literary Festival 2020
    • Campus Convo
    • Careers After Corona
    • Express Expressions
    • Q&A With Prabhu Chawla
    • ThinkEdu Awards 2020
  • Web Stories
  • edex_worksEDEXWORKS
ADVERTISEMENT
Vaccine

Published: 03rd November 2021     

Covaxin approved for emergency use by WHO. What does this mean for Indian students?

Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant

Edex Live
Edex Live
f_icon t_icon i_icon l_icon koo_icon whatsapp_icon email_icon Google News

Share Via Email

Covaxin

Image for representation | Pic: Express

With the World Health Organisation's (WHO) Technical Advisory Group (TAG) recommending Emergency Use Listing (EUL) for Bharat Biotech's COVID-19 vaccine Covaxin, it is great news for Indian students who are waiting to go abroad. While countries like Guyana, Mexico, the Philippines, Iran, Nepal, Mauritius, Paraguay, Zimbabwe, Sri Lanka, Australia, Greece, Oman and Estonia had already approved of the vaccine, many other countries were waiting for the WHO nod before stamping their approval.

Now that WHO has approved the vaccine, it can be expected that several other countries, including the United States, United Kingdom and Canada are likely to allow students jabbed with both doses of Covaxin to travel and study there. These countries are among the most popular study abroad destinations for Indian students.

But what is this the EUL all about? The Technical Advisory Group is an independent advisory group that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure. The WHO had been in the process of evaluating Covaxin's clinical trial data for approving the EUL. After seeking certain "additional clarifications" from Bharat Biotech on October 26, the advisory body reviewed the "risk-benefit assessment" and approved it for EUL on November 3.

Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant. In June, Bharat Biotech said it concluded the final analysis of Covaxin efficacy from Phase 3 trials. Bharat Biotech's Covaxin and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India.

telegram
TAGS
Vaccine COVID-19 COVAXIN

O
P
E
N

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
telegram
ADVERTISEMENT
Write to us!

If you have campus news, views, works of art, photos or just want to reach out to us, just drop us a line.

newsletter_icon
Mailbox
edexlive@gmail.com
fb_icon
Facebook
twitter_icon
Twitter
insta_icon
Instagram
ADVERTISEMENT
Facebook
ADVERTISEMENT
Tweets by Xpress_edex
ADVERTISEMENT
ADVERTISEMENT

FOLLOW US

The New Indian Express | The Morning Standard | Dinamani | Kannada Prabha | Samakalika Malayalam | Cinema Express | Indulgexpress | Events Xpress

Contact Us | About Us | Privacy Policy | Terms of Use

Home | Live Now | Live Story | Campus Trip | Coach Calling | Live Take

Copyright - edexlive.com 2023. All rights reserved. Website Designed, Developed & Maintained by Express Network Private Ltd.